Clinical Trials Directory

Trials / Unknown

UnknownNCT02025673

Study of Betatrophin Levels in Patients With Type 2 Diabetes and Gestational Diabetes and Healthy Subjects

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
Qingdao University · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

Betatrophin is a newly identified hormone that promotes pancreatic beta cell proliferation, improves glucose tolerance and regulates lipids metabolism. A recent study showed that circulating concentrations of betatrophin doubled in type 1 diabetes. The objective of this study is to investigate the association of serum betatrophin levels with the progression of diabetic retinopathy in patients with type 2 diabetes and the level of betatrophin in gestational diabetes patients and pregnant women.

Detailed description

200 subjects were recruited in this study and divided into six groups for comparison of the serum betatrophin. 70 healthy subjects and 20 healthy young volunteers were enrolled for investigating the role of betatrophin in energy homeostasis and the circadian rhythm. 50 patients with type 2 diabetes were classified into three groups by the stage of diabetic retinopathy. Rank test was used to analyze the correlation between the progression of diabetic retinopathy and circulating betatrophin. Betatrophin were measured by a commercially available enzyme-linked immunosorbent assay and confirmed via Western Blot.

Conditions

Timeline

Start date
2013-08-01
Primary completion
2014-06-01
Completion
2014-07-01
First posted
2014-01-01
Last updated
2014-01-01

Source: ClinicalTrials.gov record NCT02025673. Inclusion in this directory is not an endorsement.